TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Y Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.